Cancer Stem Cell News Volume 3.16 | Apr 30 2014

    0
    16
    Cancer Stem Cell News 3.16 April 30, 2014

    Cancer Stem Cell News

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  Cancer Stem Cell News on Twitter

     
    TOP STORY
    Aberrant Self-Renewal and Quiescence Contribute to the Aggressiveness of Glioblastoma
    Researchers screened a large panel of glioblastoma cultures cultivated under stem cell-permissive conditions and identified several cell lines with enhanced self-renewal capacity. These cell lines were capable of matrix-independent growth and form fast-growing, orthotopic tumors in mice. [J Pathol] Abstract
    NeuroCult™ for Brain Tumor Research - View Publications

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    miR-145 Inhibits Migration and Invasion of Glioma Stem Cells by Targeting ABCG2
    Scientists identified the effects and mechanisms of miR-145 on the migration and invasion of glioma stem cells (GSCs). Their investigations revealed that miR-145 was low expressed in malignant glioma tissues and their corresponding GSCs. [Neuromolecular Med] Abstract

    PI3K and Bcl-2 Inhibition Primes Glioblastoma Cells to Apoptosis through Down-Regulation of Mcl-1 and Phospho-BAD
    ABT-263 (Navitoclax), an orally available small-molecule Bcl-2 inhibitor, and GDC-0941, a phosphatidylinositol 3-kinase (PI3K) inhibitor, were used to treat established glioblastoma and glioblastoma neurosphere cells, alone or in combination. Combination treatment abrogated the ability of stem-cell like glioma cells to form neurospheres. [Mol Cancer Res] Abstract

    SPARC Was Overexpressed in Human Endometrial Cancer Stem-Like Cells and Promoted Migration Activity
    Scientists performed microarray expression analysis to screen for up-regulated genes in cancer stem cells using a set of RK12V-side-population (SP) cells and -non-SP cells. [Gynecol Oncol] Abstract

    Enhanced Antitumor Efficacy of an Oncolytic Herpes Simplex Virus Expressing an Endostatin-Angiostatin Fusion Gene in Human Glioblastoma Stem Cell Xenografts
    The use of a herpes simplex virus carrying endostatin-angiostatin as a novel therapeutic targeting strategy for glioblastoma-derived cancer stem cells was investigated. [PLoS One] Full Article

    Evaluation of Cancer Stem Cell Markers CD133, CD44, CD24: Association with AKT Isoforms and Radiation Resistance in Colon Cancer Cells
    Researchers assessed the connection between EGFR, CD133, CD24, and CD44 expression levels and radiation sensitivity, and furthermore analyzed the influence of AKT isoforms on the expression patterns of these markers, to better understand the underlying molecular mechanisms in the cell. [PLoS One] Full Article

    EZH2-Specific MicroRNA-98 Inhibits Human Ovarian Cancer Stem Cell Proliferation via Regulating the pRb-E2F Pathway
    An expression plasmid of enhancer of zeste homolog 2 (EZH2)-targeted microRNA-98 was constructed and transfected into human ovarian cancer stem cells. Seventy-two hours after transfection, cell growth was inhibited and arrested at the G0/G1 transition. p21CIPI/WAF1 was up-regulated, while the CDK2/cyclin E complex and c-Myc were down-regulated. [Tumor Biol] Abstract

    Cell-State Transitions Regulated by SLUG Are Critical for Tissue Regeneration and Tumor Initiation
    In the absence of SLUG, stem cells fail to transition into basal progenitor cells, while existing basal progenitor cells undergo luminal differentiation; together, these changes result in abnormal mammary architecture and defects in tissue function. Furthermore, scientists showed that in the absence of SLUG, mammary stem cell activity necessary for tissue regeneration and cancer initiation is lost. [Stem Cell Rep] Full Article

    Regulated Splicing of the a6 Integrin Cytoplasmic Domain Determines the Fate of Breast Cancer Stem Cells
    Researchers report that a CD44high/CD24low population, enriched for cancer stem cells, is comprised of distinct epithelial and mesenchymal populations that differ in expression of the two a6 cytoplasmic domain splice variants: a6A and a6B. [Cell Rep] Full Article | Graphical Abstract

    Protocol and Data: Serum-Free, 3D Suspension Assay for Breast Cancer Cells

     
    REVIEWS
    Cancer Stem Cells and Their Implication in Breast Cancer
    There is a need for specific anti-cancer stem cell therapies, and numerous authors are investigating new targets to this end, as reported in this review. It is also necessary for clinical trials to be undertaken to allow this new knowledge to be applied in the clinical setting. [Eur J Clin Invest] Abstract

    Hallmarks in Colorectal Cancer: Angiogenesis and Cancer Stem-Like Cells
    The authors review the current knowledge regarding the molecular phenotype of colorectal cancer cancer cells, as well as discuss the mechanisms contributing to their maintenance. [World J Gastroenterol] Full Article

    Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

     
    INDUSTRY NEWS
    PIXUVRI® Launched in UK for Adult Patients with Multiply Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
    Cell Therapeutics, Inc. announced the launch of PIXUVRI® (pixantrone), the first new treatment for adult patients in the United Kingdom (UK) with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. [Cell Therapeutics, Inc.] Press Release

    OncoGenex Announces Top-Line Survival Results of Phase III SYNERGY Trial Evaluating Custirsen for Metastatic Castrate-Resistant Prostate Cancer
    OncoGenex Pharmaceuticals, Inc. announced results from the Phase III SYNERGY trial. Top-line survival results indicate that the addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet the primary endpoint of a statistically significant improvement in overall survival in men with metastatic castrate-resistant prostate cancer, compared to docetaxel/prednisone alone. [OncoGenex Pharmaceuticals, Inc.]
    Press Release

    Novartis Gains FDA Approval for Zykadia(TM), First Therapy for Patients with ALK+ NSCLC Previously Treated with the ALK Inhibitor Crizotinib
    Novartis announced that the US Food and Drug Administration (FDA) has approved Zykadia(TM) for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. [Novartis AG] Press Release

    From our sponsor:
    View immunology lectures, protocols and other resources on the Human Immunology Portal.

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW Gordon Research Conference: Cell Polarity Signaling
    June 1-6, 2014
    Waltham, United States

    Visit our events page to see a complete list of events in the cancer stem cell community.

     
    JOB OPPORTUNITIES
    NEW Postdoctoral Researcher – Cancer Genomics (University of Chicago)

    NEW Research Technologist – hPSC (STEMCELL Technologies Inc.)

    Postdoctoral Fellow – Cancer Development and Stem Cells (University of Texas MD Anderson Cancer Center)

    Postdoctoral Position – Cancer Stem Cells (Queen Mary University of London)

    Postdoctoral Fellow – Cancer Biology (University of Cincinnati)

    Faculty Position – Cell, Developmental and Cancer Biology (Oregon Health & Science University)

    Postdoctoral Research Associate – Extracellular Microenvironment in Cancer (Institute of Translational Medicine, University of Liverpool)

    Postdoctoral Fellowships – Cancer Research (German Cancer Research Center [DKFZ])

    Faculty Positions – Cancer Research (Stephenson Cancer Center at the University of Oklahoma)

    Postdoctoral Position – Cancer Biology (IRCAN)

    Postdoctoral Position – Stem Cells and Cancer (Brigham & Women’s Hospital – Harvard Medical School)

    Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

    Research Associate – Cell Separation (STEMCELL Technologies Inc.)

    Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

    Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)


    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

    Comments or Suggestions? Email Comments or suggestions? Submit your feedback here

    Learn more about Cancer Stem Cell News: Archives | Events | Contact Us